Mr. Gerald Tritt reports

JOLT HEALTH INC., LETTER TO THE SHAREHOLDERS

Jolt Health Inc. has provided the following letter to shareholders, outlining the company's advancements and an update on the direction of the company.

To the shareholders of Jolt Health,

We welcome this opportunity to provide our shareholders with a comprehensive outlook of Jolt's efforts in building upon its existing portfolio and establishing its future strategic imperatives by building upon Jolt's existing product portfolio, which is primarily focused on over the counter products.

Jolt is exploring current opportunities in expanding its health and wellness portfolio by exploring opportunities in the AI (artificial intelligence) drug development and pharmaceutical sectors. The company is working to identify and assess biotechnology and pharmaceutical solutions to address a myriad of health concerns, a catalyst for growth in this bourgeoning market.

The company believes that it is at the beginning of a health and wellness renaissance and are looking to participate in the coming wave of interest. Focusing on business fundamentals of strong growth, service and operational excellence as the path to deliver meaningful results, including environmental and social impact, is a key driver of how the company plans to create shareholder value over the long term.

In addition, the company would like to announce that Cody Corrubia has joined the board as a director. In accepting his resignation from the board, the company wishes Mark Tommasi well in his future endeavours.

We are also pleased to announce a private placement financing of up to 50 million units of the company at a price of one cent per unit for aggregate gross proceeds of up to $500,000.

Each unit will comprise one common share in the capital of the company and one-half a warrant. Each whole warrant entitles the holder thereof to purchase one common share at a price of five cents per common share for a period of two years following the closing date of the offering, subject to accelerated expiry as described herein. If, at any time, the closing price of the company's common shares is greater than 15 cents per common share for 10 consecutive days, including days where there is no trading, the company may provide written notice to the holders that the expiry of the warrants shall be accelerated to a date that is not less than 30 days from the date of the warrant acceleration notice.

Thank you for your continued support. We are excited to have you along for the journey.

On behalf of the board of directors,

Gerald Tritt

President and chief executive officer

About Jolt Health Inc.

With a focus on the global health and wellness markets, Jolt Health was founded in 2023, with a mission to bring to market innovative products that enhance health and wellness and provide an improved quality of life. Jolt Health holds exclusive licences to produce market, package, sell and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom and North America.

We seek Safe Harbor.